


# Accepted Manuscript

Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review

Peter M. Ellis, MBBS, PhD, Emily T. Vella, PhD, Yee C. Ung, MD



PII: S1525-7304(17)30043-8

DOI: [10.1016/j.clc.2017.02.001](https://doi.org/10.1016/j.clc.2017.02.001)

Reference: CLLC 606

To appear in: *Clinical Lung Cancer*

Received Date: 17 August 2016

Revised Date: 1 February 2017

Accepted Date: 7 February 2017

Please cite this article as: Ellis PM, Vella ET, Ung YC, Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review, *Clinical Lung Cancer* (2017), doi: 10.1016/j.clc.2017.02.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer:  
A Systematic Review**

Peter M. Ellis MBBS, PhD<sup>a</sup>, Emily T. Vella PhD<sup>b</sup>, Yee C. Ung MD<sup>c</sup>

- a. Medical Oncology, Juravinski Cancer Centre, and Department of Oncology, McMaster University, Hamilton, Ontario
- b. Program in Evidence-Based Care, McMaster University, Hamilton, Ontario
- c. Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario

**Running header:** IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED NSCLC

**Correspondence:**

Dr. Peter Ellis c/o Dr. Emily Vella

Program in Evidence-Based Care, McMaster University, Juravinski Hospital

G Wing, 2<sup>nd</sup> Floor, 711 Concession Street, Hamilton, ON L8V 1C3

Phone: 905-527-4322 x42846, Fax: 905-526-6775, Email: [vellaem@mcmaster.ca](mailto:vellaem@mcmaster.ca)  
[ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca)

**Conflicts of Interest and Source of Funding:**

P.M.E. was an author on the American Society for Clinical Oncology guideline for stage IV non-small cell lung cancer<sup>1</sup> and is a member of a data safety monitoring committee for Celgene for a trial evaluating maintenance therapy with Abraxane. For the remaining authors none were declared.

The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ontario Ministry of Health and Long-Term Care.

Download English Version:

<https://daneshyari.com/en/article/5581320>

Download Persian Version:

<https://daneshyari.com/article/5581320>

[Daneshyari.com](https://daneshyari.com)